Shares of BioNTech rose after the company said it plans to deliver over 2.2 billion vaccination doses this year.
Good news for BioNTech shareholders.
As of 1:00 p.m. today, the company's stock rose over 14 percent today after BioNTech said they signed agreements for about 2.2 billion doses this year.
In a press release, the company stated that along with partner Pfizer, they've crossed the one billion mark for COVID-19 vaccinations after only six months.
BioNTech also stated that over a billion doses have been ordered for 2022 and beyond.
Ugur Sahin, BioNTech Cofounder, also notes that they're expanding their vaccine supply to over 100 countries.
"To address the ongoing pandemic, we are expanding the supply of our COVID-19 vaccine to more than 100 countries and regions worldwide, including enhancing access to low- and middle-income countries. At the same time, we further developed our oncology pipeline, including the recent initiation of randomized Phase 2 trials for two FixVac programs."
The statement also says the companies are conducting multiple clinical trials on the effects of the vaccine on children between 6 months to 11 years old.
Kristen French Centre Battling Online Luring
Niagara's Crime Severity Rate Drops
Man Dies in Niagara Falls Motorcycle Crash
2nd Niagara Falls Murder Suspect Arrested
Suspect Wanted After Cables Cut
Candidates Splurge on Election Signs
Homeless, City Finances Top Candidate's Concerns
Police Investigation Resolved